

## Additional disclosures

Five-year history – financial performance and key metrics

### Group financial performance

Half-year ended 31 December <sup>1</sup> (\$m)	2024	2023	2022	2021	2020
<b>Summarised income statement</b>					
Revenue	23,490	22,673	22,558	17,758	17,774
EBIT (after interest on lease liabilities)	2,176	2,081	2,053	1,796	2,023
Other finance costs	(83)	(81)	(62)	(48)	(60)
Income tax expense	(626)	(575)	(607)	(535)	(573)
Profit after tax from discontinued operations	-	-	-	-	-
NPAT (including discontinued operations)	1,467	1,425	1,384	1,213	1,390
<b>Summarised balance sheet</b>					
Total assets <sup>2</sup>	27,710	27,291	27,608	25,231	25,518
Total liabilities <sup>2</sup>	18,737	18,872	19,514	17,488	15,907
Net assets	8,973	8,419	8,094	7,743	9,611
Net debt / (cash)	3,990	3,888	4,674	2,863	(529)
<b>Summarised cash flow statement</b>					
Operating cash flows	2,575	2,898	1,971	1,556	2,216
Add/(less): Net capital expenditure	(555)	(570)	(578)	(405)	(243)
Add/(less): Other investing cash flows	5	(316)	(28)	(202)	(9)
Add/(less): Total investing cash flows	(550)	(886)	(606)	(607)	(252)
Free cash flows	2,025	2,012	1,365	949	1,964
Add/(less): Financing cash flows	(2,373)	(1,881)	(1,438)	(3,349)	(2,197)
Net increase/(decrease) in cash	(348)	131	(73)	(2,400)	(233)
<b>Distributions to shareholders (cents per share)</b>					
Interim ordinary dividend	95	91	88	80	88
<b>Key performance metrics</b>					
Earnings per share (cents per share)	129.4	125.8	122.3	107.3	122.9
Earnings per share from continuing operations excluding sig. items (cents per share)	129.4	125.8	122.3	107.3	125.0
Operating cash flow per share (cents per share)	227.1	255.8	174.1	137.5	195.9
Cash realisation ratio (excluding sig. items) (%)	108	126	89	79	102
Return on equity (R12, %)	31.2	31.4	32.8	24.8	19.9
Return on equity (R12, %) (excluding sig. items)	31.2	31.4	32.8	24.8	24.7
Net tangible asset backing per share (\$ per share) <sup>2</sup>	3.39	2.98	3.01	3.35	5.08

<sup>1</sup> See Additional Disclosures on page 50 for relevant definitions.

<sup>2</sup> 2022 has been restated to reflect the adjustments to the provisional acquisition accounting for Australian Pharmaceuticals Industries Pty Ltd.

## Additional disclosures

Five-year history – financial performance and key metrics

### Divisional key performance metrics

Half-year ended 31 December (\$m)	2024	2023	2022	2021	2020
<b>Bunnings Group</b>					
Revenue	10,280	9,963	9,792	9,209	9,054
EBITDA <sup>1</sup>	1,799	1,748	1,721	1,677	1,669
Depreciation and amortisation	(411)	(408)	(387)	(362)	(337)
Interest on lease liabilities	(66)	(58)	(56)	(56)	(58)
EBT <sup>1</sup>	1,322	1,282	1,278	1,259	1,274
EBT margin <sup>1</sup> (%)	12.9	12.9	13.1	13.7	14.1
ROC <sup>1</sup> (R12, %)	71.5	65.8	70.7	79.0	76.6
Capital expenditure (cash basis)	234	135	226	196	219
Total sales growth (%)	3.1	1.7	6.3	1.7	24.3
Total store sales growth <sup>2</sup> (%)	3.5	1.9	5.1	1.0	24.8
Store-on-store sales growth <sup>2</sup> (%)	3.4	1.2	2.8	1.5	27.7
Digital sales <sup>3</sup> (%)	6.3	5.1	4.4	6.6	4.3
Safety (R12, TRIFR)	14.4	15.9	16.9	12.5	10.0
Scope 1 and 2 market-based emissions (kt)	17	27	31	54	54
Scope 1 and 2 location-based emissions (kt)	81	86	92	107	115
<b>Kmart Group<sup>4</sup></b>					
Revenue	6,108	5,986	5,714	4,605	5,441
EBITDA <sup>5</sup>	947	895	765	513	818
Depreciation and amortisation	(262)	(252)	(250)	(247)	(283)
Interest on lease liabilities	(41)	(42)	(40)	(44)	(48)
EBT <sup>5</sup>	644	601	475	222	487
EBT margin <sup>5</sup> (%)	10.5	10.0	8.3	4.8	9.0
ROC <sup>5</sup> (R12, %)	65.9	58.8	43.3	34.7	35.5
Capital expenditure (cash basis)	66	85	62	62	81
Total sales growth <sup>6,7</sup> (%)	2.0	5.0	24.5	(10.2)	5.6
Comparable sales growth <sup>6,7</sup> (%)	1.9	5.3	13.7	(2.2)	10.9
Online penetration <sup>7</sup> (%)	9.7	9.5	9.4	17.5	10.9
Safety (R12, TRIFR)	6.1	7.3	7.0	8.6	10.6
Scope 1 and 2 market-based emissions (kt)	86	91	115	120	132
Scope 1 and 2 location-based emissions (kt)	105	112	119	135	143

<sup>1</sup> Includes net property contribution for 2024 of (\$1) million; 2023 of nil; 2022 of \$35 million; 2021 of \$41 million; and 2020 of \$1 million.

<sup>2</sup> Includes cash, trade and online sales, excludes property income and sales related to Trade Centres, Frame & Truss, Tool Kit Depot and Beaumont Tiles. Store-on-store sales growth in 2023, 2022, 2021 and 2020 excludes stores in months that were impacted by extended periods of temporary closure in New South Wales, Australian Capital Territory, Victoria and New Zealand.

<sup>3</sup> Digital sales includes online sales, app sales and marketplace sales expressed as a share of total sales including marketplace.

<sup>4</sup> 2020 includes Catch.

<sup>5</sup> 2020 excludes \$34 million of pre-tax restructuring costs and provisions in Target.

<sup>6</sup> Based on retail periods (rather than Gregorian reporting). Comparable store sales recognise layby sales at point of deposit. Total sales recognise layby sales in accordance with the guidelines set by the Australian Accounting Standards. Comparable growth calculation in 2023, 2022 and 2021 excludes stores that were temporarily closed as a result of COVID-19 restrictions for the duration of the closure period, where the closure period was longer than two weeks.

<sup>7</sup> 2020 to 2023 sales metrics have been restated to report at a Kmart Group level, excluding Catch.

## Additional disclosures

Five-year history – financial performance and key metrics

### Divisional key performance metrics (continued)

Half-year ended 31 December (\$m)	2024	2023	2022	2021	2020
<b>Chemicals, Energy and Fertilisers</b>					
Chemicals revenue <sup>1</sup>	704	628	860	642	489
Energy revenue <sup>1</sup>	260	262	265	252	206
Fertilisers revenue <sup>1</sup>	246	215	277	183	135
Total revenue <sup>1</sup>	1,210	1,105	1,402	1,077	830
EBITDA	255	229	372	262	202
Depreciation and amortisation	(77)	(56)	(48)	(43)	(42)
Interest on lease liabilities	(1)	(1)	-	(1)	-
EBT	177	172	324	218	160
ROC (R12, %)	12.8	16.2	23.0	19.6	18.1
ROC (R12, %) (excluding ALM)	32.5	32.9	40.3	32.2	29.0
Capital expenditure (cash basis) <sup>2</sup>	204	255	272	238	53
Safety (R12, TRIFR)	4.6	3.7	3.0	4.2	3.2
Scope 1 and 2 market-based emissions (kt)	421	419	433	370	454
Scope 1 and 2 location-based emissions (kt)	426	417	433	373	455
 Sales volumes <sup>1</sup> ('000 tonnes)					
Chemicals	571	584	562	565	550
LPG & LNG	101	104	108	109	115
Fertilisers	396	302	248	286	274
 <b>Officeworks</b>					
Revenue	1,760	1,681	1,651	1,580	1,523
EBITDA	166	161	152	142	156
Depreciation and amortisation	(70)	(67)	(62)	(55)	(51)
Interest on lease liabilities	(9)	(8)	(5)	(5)	(5)
EBT	87	86	85	82	100
EBT margin (%)	4.9	5.1	5.1	5.2	6.6
ROC (R12, %)	18.3	18.3	17.3	19.6	23.4
Capital expenditure (cash basis)	29	28	26	28	26
Total sales growth (%)	4.7	1.8	4.6	3.7	23.6
Online penetration (%)	36.0	34.7	34.5	46.0	37.1
Safety (R12, TRIFR)	7.4	4.6	6.1	5.5	7.3
Scope 1 and 2 market-based emissions (kt)	11	12	14	15	17
Scope 1 and 2 location-based emissions (kt)	14	14	15	18	20

<sup>1</sup> Revenue and external sales volumes exclude intra-division sales.

<sup>2</sup> Includes WesCEF's share of capital expenditure for the development of the Covalent lithium project in 2024 of \$110 million, 2023 of \$164 million, 2022 of \$204 million, and 2021 of \$139 million. 2024, 2023, 2022 and 2021 include capitalised interest of \$14 million, \$13 million, \$21 million and \$16 million respectively. Includes capital expenditure made prior to the final investment decision in 2020 of \$15 million.

## Additional disclosures

Five-year history – financial performance and key metrics

### Divisional key performance metrics (continued)

Half-year ended 31 December (\$m)	2024	2023	2022	2021	2020
<b>Industrial and Safety<sup>1</sup></b>					
Revenue	990	1,009	978	944	898
EBITDA <sup>2</sup>	88	92	89	80	76
Depreciation and amortisation	(41)	(41)	(40)	(37)	(37)
Interest on lease liabilities	(2)	(2)	(2)	(2)	(2)
EBT <sup>2</sup>	45	49	47	41	37
EBT margin <sup>2</sup> (%)	4.5	4.9	4.8	4.3	4.1
ROC <sup>2</sup> (R12, %)	8.0	7.9	8.1	6.5	5.4
Capital expenditure (cash basis)	28	42	31	25	30
Safety (R12, TRIFR)	1.7	3.2	4.0	3.1	4.5
Scope 1 and 2 market-based emissions (kt)	13	13	14	14	12
Scope 1 and 2 location-based emissions (kt)	12	13	13	14	13
<b>Wesfarmers Health</b>					
Revenue	3,022	2,774	2,778	n.r.	n.r.
EBITDA <sup>3</sup>	68	66	66	n.r.	n.r.
Depreciation and amortisation	(37)	(37)	(36)	n.r.	n.r.
Interest on lease liabilities	(3)	(2)	(3)	n.r.	n.r.
EBT <sup>3</sup>	28	27	27	n.r.	n.r.
EBT margin <sup>3</sup> (%)	0.9	1.0	1.0	n.r.	n.r.
ROC <sup>3</sup> (R12, %)	3.1	3.5	n.r.	n.r.	n.r.
Capital expenditure (cash basis)	26	20	20	n.r.	n.r.
Safety (R12, TRIFR)	3.9	5.9	n.r.	n.r.	n.r.
Scope 1 and 2 market-based emissions (kt)	6	5	7	n.r.	n.r.
Scope 1 and 2 location-based emissions (kt)	5	5	7	n.r.	n.r.
<b>Catch<sup>4</sup></b>					
		<i>Reported separately</i>			<i>Included in Kmart Group results</i>
Gross transaction value	258	317	451	616	610
Gross transaction value growth (%)	(18.6)	(29.7)	(26.8)	1.0	95.6
Revenue	104	136	219	315	329
EBITDA <sup>5</sup>	(27)	(27)	(93)	(30)	(4)
Depreciation and amortisation	(11)	(13)	(14)	(13)	(10)
Interest on lease liabilities	(1)	(1)	(1)	(1)	(1)
EBT <sup>5</sup>	(39)	(41)	(108)	(44)	(15)
Capital expenditure (cash basis)	1	3	10	19	n.r.
Safety (R12, TRIFR)	14.3	4.3	2.4	3.1	n.r.
Scope 1 and 2 market-based emissions (kt)	1	1	2	1	n.r.
Scope 1 and 2 location-based emissions (kt)	1	1	2	1	n.r.

<sup>1</sup> Includes results from Greencap prior to its divestment on 1 August 2022.

<sup>2</sup> 2024 includes \$7 million of restructuring costs.

<sup>3</sup> 2024 includes \$4 million of restructuring costs.

<sup>4</sup> Catch is included in Kmart Group in 2020.

<sup>5</sup> 2023 includes \$4 million and 2022 includes \$33 million of restructuring costs.